Rare Daily Staff
Shorla Pharma said it raised $8.3 million in a series A financing to advance its oncology pipeline focused on rare and pediatric cancers.
The European venture capital firm Seroba Life Sciences led the financing with additional investment from Irish and Canadian based family offices and participation from Enterprise Ireland.
Shorla has developed innovative oncology drugs with a focus on rare, orphan and pediatric cancers, delivering more effective products in indications where existing treatments are sub-optimal for the target patients.
The company has advanced pipeline of innovative drug products to treat a number of unmet patient needs. The funding will support the advancement of the product pipeline, along with expansion of technical and commercial operations in both Ireland and the United States.
Shorla was founded by Sharon Cunningham and Orlaith Ryan. The company’s name is a combination of the founders first names. Both were formerly with EirGen Pharma. Shorla is based in Questum, a Clonmel, Ireland based acceleration center.
Shorla co-founder Sharon Cunningham said the investment will “provide the necessary resource to further advance the product pipeline through health authority registration and commercialization, which will ultimately create valuable and clinically impactful treatments that improve patient outcomes.”
Photo: Shorla Pharma co-founders by Sharon Cunningham and Orlaith Ryan
Stay Connected
Sign up for updates straight to your inbox.